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Amp Ampicilin     氨苄青霉素 
cDNA  Complementary Deoxyribonucleic acid   互补 DNA 
DAB   diacetylbenzene   二氨基联苯胺 
DAMP   Damage associated molecular partern 损伤相关的分子模式 
ddH 2 O   double-distilled water 双蒸水 
DEPC Diethylpyrocarbonate   焦碳酸二乙酯 
DTT   Dithiothreitol. 二硫苏糖醇 
E.coli   Escherichia coli   大肠埃希菌 
EDTA   Ethylendiaminotetraacetic acid   乙二胺四乙酸二钠 
ELISA Enzyme-linked immunosorbent assay 酶联免疫吸附试验 
FCM   Flow cytometry 流式细胞术 
FBS fetal bovine serum   胎牛血清 
FITC   Fluorescein isothiocyanate   异硫氰酸荧光素 
GA Gouty arthritis 痛风性关节炎 
GST Glutathione S-transferase   谷胱甘肽硫转移酶 
HRP   Horseradish peroxidase 辣根过氧化物酶 
IL   Interleukin 白细胞介素 
IPTG   Isopropyl β-D-thiogalactoside   异丙基硫代-β -半乳糖苷 
kD   kilo-Dalto   千道尔顿 
LB   lysogeny broth   溶菌肉汤 
LPS   Lipopolysaccharide   脂多糖 
MDSC   marrow drived suppressor cell   髓系来源的抑制细胞 
mg   Milligram   毫克 
min   Minute   分钟 
ml   Millilitre   毫升 
mRNA   messenger RNA   信使 RNA 
















OD   optical density   光密度 
PAGE Polyacrylamide gel electrophoresis   聚丙烯酰胺凝胶电泳 
PAMP   Pathogen associated molecular partern   病原相关分子模式 
PBS   Phosphate buffered saline   磷酸盐缓冲液 
PVDF   Polyvinylidene fluoride   聚偏二氟乙烯 
rpm Revolutions per minute   转/分钟 
real-timePCR real-time Polymerase chain reaction 实时定量聚合酶链反应 
RT-PCR Reverse transcription polymerase chainreaction 逆转录聚合酶链反应 
SDS   Sodium dodecyl sulfate   十二烷基磺酸钠 
TLR   Toll Like Receptors Toll 样受体 
TNF-α Tumor necrosis factor-α 肿瘤坏死因子α  
TEMED N,N,N',N'-Tetramethylethylenediamine N,N,N',N'-四甲基二乙胺 
Tris   Tris(hydroxymethyl) aminomethane   三羟甲基氨基甲烷 


















研究目的：以 MSU 诱导的小鼠实验性急性痛风为痛风研究模型，来探讨 IL-33
在急性痛风中的作用及其机制。 
研究方法和结果： 
1.重组小鼠 IL-33 的原核表达以及纯化 
GST-IL-33 融合蛋白经过原核表达、纯化，去除 GST 标签等步骤，获得了较
高纯度的的 mrIL-33。 
2.对急性痛风患者血清中 IL-33 的研究 
通过收集临床急性痛风患者 41 例（男 39 例，女 2 例）年龄 26～91 岁，平
均 58.3 岁和 44 例年龄、性别与之匹配的健康志愿者的血清标本，检测血清中
IL-33 的含量。结果显示急性痛风患者血清中 IL-33 的含量明显高于健康志愿者，
并且在痛风患者中，血清中 IL-33 的含量与 CRP 值呈正相关。 
3.急性痛风中 IL-33 的来源及产生机制 
本实验室前期数据表明急性痛风患者的 WBC 基本不表达 IL-33。本课题，
我们分别用 MSU 以及促炎因子（IL-1β 和 TNFα）刺激关节滑膜成纤维细胞，实
验结果表明①IL-1β 和 TNF-α 共同刺激关节滑膜成纤维细胞显著表达 IL-33，②
MSU 同样可以刺激关节滑膜成纤维细胞高表达 IL-33。 
4.IL-33 在小鼠实验性急性痛风中的效应研究 
4.1. IL-33 明显缓解 MSU 诱导的小鼠急性痛风 
将 6-8 周的雄性 C57BL/6 小鼠分为 PBS 组、MSU 组、IL-33 组和 IL-33+MSU
组共四组，PBS 组和 MSU 组的小鼠先 PBS 预处理 4 天，IL-33 组和 IL-33+MSU
组的小鼠先用 2µg/d rIL-33 预处理 4 天，第四天预处理后，立即将 MSU 组和
IL-33+MSU 组腹腔注射给予 3mg MSU，PBS 组和 IL-33 组腹腔注射 PBS 做相应
的对照。16h 后收集腹腔里面的细胞和上清。中性粒细胞作为痛风的主要效应细
胞，我们通过分析各组腹腔中募集的中性粒细胞的总数，发现 IL-33+MSU 组的
中性粒细胞数明显低于 MSU 组；此外，IL-1β 作为痛风关键促炎因子，我们检
















组，综上所述，我们得出结论：IL-33 明显缓解了 MSU 诱导的急性痛风。 
4.2.IL-33 促进抑炎因子的表达 
小鼠在经 IL-33 预处理后,收集的腹腔上清进行 ELISA 检测,结果显示： 
IL-33+MSU 组的 IL-13 和 IL-10 等抑炎因子表达量明显高于 MSU 组。 
4.3.IL-33 诱生 MDSCs 
小鼠在经 IL-33 腹腔注射预处理后,收集的腹腔细胞,流式分析可见大量表
面标志为 CD11b+Gr-1+F4/80+ MDSCs。 
结论 
1.IL-33 在急性痛风中表达上调,并与疾病活动度呈正相关。 
2.MSU 及促炎因子（IL-1β 和 TNFα）刺激关节滑膜成纤维细胞显著表达
IL-33。 
3.注射外源性 IL-33 显著缓解 MSU 诱导的小鼠急性痛风。 
4.在MSU诱导的小鼠急性痛风中,IL-33作为机体自反馈抑炎因子,诱生具有免
疫抑制作用的细胞群 MDSCs 

















Research objective: we assess the effects and mechanisms of IL-33 on theMSU 
crystals -induced experimental acute gout that mimics the human acute gout . 
Research methods and result: 
1. The production and purification of mouse IL-33 fusion protein 
GST-IL-33 fusion protein was expressed by E. coli, purified by 
glutathione-affinity chromatography and the GST tag was cleaved with thrombin. 
2. The expression of IL-33 in serum of patients with acute gout 
A total of 41 patients diagnosed with acute gout (39 men and 2women, age 26-91, 
mean 58.3 years) were included. The results were compared with a population of 
44 healthy volunteers (controls) matched for sex and age. The results of this study 
revealed that the IL-33 concentration in serum of patients was significantly higher 
than that of healthy volunteers and was positively correlated to CRP. 
3. The generation and mechanism of IL-33 in acute gout 
Previous date showed that Peripheral blood leukocytes were not the source of 
IL-33 production. Then, the synovial fibroblasts were stimulated with PBS, MSU 
crystals or the proinflammatory cytokines(IL-1βand TNF-α). The results revealed the 
expression of IL-33 in synovial fibroblasts was markedly increased following MSU 
crystal or IL-1βcombined with TNF-α treatment. 
4.The role of IL-33 in murine experimental acute gout 
4.1. IL-33 reduced the development of theMSU crystals -induced experimental 
acute gout in mice 
Male C57BL/6 mice (6–8 weeks old) were divided into the PBS group, MSU 
group, IL -33 group and IL-33 + MSU group. The mice of PBS group and MSU group 
were daily administered an intraperitoneal (IP) injection of PBS for 4 days; the mice 
of IL -33 group and IL-33 + MSU group weredaily administered an intraperitoneal (IP) 
















IL-33 + MSU group were administered an intraperitoneal (IP) injection of 3mg 
MSUafter pretreatment; the mice of PBS group and IL-33 group were administered an 
intraperitoneal (IP) injection of PBS after pretreatment. At 16 hours after MSU 
stimulation, peritoneal exudate cells were harvested by lavage with 3 ml PBS.Cells 
were analyzed by flow cytometry and lavage fluids were retained for cytokineassay. 
Neutrophils act as the main effector cells in gout, IL-1βis the key proinflammatory 
factor. In this study, neutrophil numbers and IL-1βconcentration in IL-33 + MSU 
group obviously decreased when compared with MSU group. From the above, we 
concluded that IL-33 reduced the development of the MSU crystals -induced 
experimental acute gout in mice.  
4.2. IL-33 promoted the expression of inflammation suppression factors 
The IL-13 and IL-10concentrationswere determined by ELISA. In this study, the  
expression of IL-13 and IL-10 in IL-33 + MSU group markedly increased when 
compared with MSU group. 
4.3. IL-33 inducedMDSCs 
The peritoneal exudate cells were analyzed by flow cytometry, In this study,the 
mice treated with rIL-33 pretreatment induced a large number of MDSCs 
Conclusion: 
1. IL-33 was highly expressed in gout and was positively correlated to CRP. 
2.The expression of IL-33 in synovial fibroblasts was markedly increased following 
MSU crystal or IL-1βcombined with TNF-α treatment. 
3. IL-33 administration significantly ameliorated the development of MSU crystals 
-induced acute gout. 
4. In the murine model of theMSU crystals-induced experimental acute gout, IL-33 
acted as the body self feedback inflammation suppression factor and induced 
a large number of MDSCs  



























































组猪源尿酸酶（pegloticase）[6]。Pegloticase 商品名为 Krystexxa，是由 savient 公






[8]等在急性痛风动物实验模型中检测到 IL-1β mRNA 的表达水平上
调，并且发现在急性痛风时期 IL-1β 的活性比痛风的其他不同时期明显增高。
2006 年，Martinon[9]等研究发现向正常野生型小鼠的腹膜腔注入 MSU 后，大量
中性粒细胞被募集到腹膜腔并聚集在 MSU 沉积部位，然而在 IL-1R-/-小鼠的腹腔
内，并未发现中性粒细胞在腹腔内的聚集现象。此外，注射 IL-1 R 阻断剂可阻
止中性粒细胞聚集于腹膜腔从而缓解痛风，然而注入 TNFα 抑制剂的小鼠中性
粒细胞在腹膜腔的聚集并未受影响。以上研究表明 IL-1β 在 MSU 引起的炎症中
扮演了关键的角色。IL-1β 作为前炎症网链中的一级细胞因子，其合成和释放过
程被严格控制，在免疫刺激条件下，首先 IL-1β 通过 MyD88 依赖 TLR 和 
MyD88 依赖 IL-1 受体信号途径由单核-巨噬细胞和树突细胞等产生，以无活性
的前体(pro-IL-1β )形式存在。当机体启动固有免疫反应时，细胞质中累积的 
pro-IL-1β 被活化的 Caspase-1 催化分解裂解成为有活性的 p17 形式，导致成熟
的 IL-1β 产生并释放至胞外，参与炎症与免疫调控，可作为固有免疫反应的起
始。可见 IL-1β 生物活性直接依赖于 Caspase-1 的活化。在痛风发病过程中，
单核/巨噬细胞在应对 MSU 的刺激中，主要由 toll 样受体（toll-like receptors，
TLRs）和 NLRP3 炎症体（由 NLRP3 支架、ASC 和 caspase-1 组成）介导 IL-1β
的活化[10]。成熟的 IL-1β 形成分为两步。第一步，MSU 通过直接激活 TLRs 或者
与某些细胞表面蛋白相互作用激活 TLRs，最终活化 NF-κB 促进 Pro-IL-1β 的生
成[11]。第二步，被单核-巨噬细胞吞噬的 MSU 在胞内激活 NLRP3 炎症体，然后

















的 IL-1 受体（IL-1R）结合激活 IL-l 信号通路和髓样分化因子（MyD88）依赖
的核因子 NF-κ B 通路[12]。促进大量的趋化因子和促炎症因子（比如 TNF-α 、
IL-6 等）的生成，通过炎症级联放大效应，促进炎症发生。进而活化和招募单























NETs 最早在 2004 年由 Brinkmann 所发现，该研究利用 IL-8、佛波醇肉豆蔻
酸乙酸酯或 LPS 刺激中性粒细胞，通过电子显微镜和免疫荧光观察发现，中性
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